Article Details

Kyverna Therapeutics Receives U.S. FDA RMAT Designation for KYV-101 in the Treatment ...

Retrieved on: 2024-08-12 20:07:24

Tags for this article:

Click the tags to see associated articles and topics

Kyverna Therapeutics Receives U.S. FDA RMAT Designation for KYV-101 in the Treatment .... View article details on hiswai:

Summary

The article details Kyverna Therapeutics’ FDA approval for KYV-101, a CAR T-cell therapy for myasthenia gravis, highlighting its implications for autoimmune disease treatment. It underscores advancements in cell therapy and regenerative medicine in the context of natural medicine practices.

Article found on: www.prnewswire.com

View Original Article

This article is found inside other hiswai user's workspaces. To start your own collection, sign up for free.

Sign Up